HPTP Phosphatase in Cancer

Back to all technologies
Download as PDF
61042
The function of protein tyrosine phosphatases and their role in cancer have been recognized for several years. In general, these phosphatases negatively regulate the oncogenic function of certain kinases by reversing pro-malignant modification of critical signaling proteins, including the kinases themselves. Notably, many solid tumors are associated with unphosphorylated EphA2. EphA2 is a tyrosine kinase that is overexpressed and functionally altered in malignant cells. The lack of cytoplasmic phosphorylation causes EphA2 to promote malignant cell growth, invasion, and survival.

Researchers at Purdue University have developed a novel diagnostic and therapeutic target for cancer diagnosis, prognosis, and treatment using a human protein tyrosine phosphatase (HPTP). HPTP is overexpressed in these aggressive cancer cells and has been shown to target EphA2 and other Eph receptors. In cell-based studies, HPTP overexpression has been demonstrated to be sufficient to cause malignant transformation. Thus, inhibitors of HPTP hold potential for targeting the large number of cancers that are associated with unphosphorylated Eph receptors.

Advantages:
-Identifies an important oncoprotein, HPTP
-Suggests novel therapeutic approaches for certain cancers involving HPTP targeting and inactivation, which would reduce HPTP activity in cancerous cells

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Cancer Detection
-Cancer Treatment
Nov 22, 2004
Utility Patent
United States
7,662,770
Feb 16, 2010

May 22, 2003
Australia
2003239585
Sep 17, 2009

May 22, 2003
PCT-Patent
WO
(None)
(None)

May 22, 2003
Canada
(None)
(None)

May 22, 2003
European Patent
(None)
(None)

May 22, 2003
Japan
(None)
(None)

May 23, 2002
Provisional-Patent
United States
(None)
(None)

(None)
RE
Hong Kong
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org